EGFR and lung cancer: Greulich et al. reported that STAT3 was activated by various EGFR mutations, including the exon 19 in-frame deletion or the exon 21 L858R point mutation, and may contribute to the oncogenic effects of these mutations in fibroblasts and human lung cancer cells [67].